Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

Company Overview

Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized immunotherapies for cancer. Its technology uses a patient’s own dendritic cells, which are immune cells that can be prepared to recognize and target that individual’s tumor.

The company’s lead product candidate is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also investigated its platform in other solid tumors, including metastatic cancers, although DCVax-L has been the company’s primary clinical development program.

Northwest Biotherapeutics was founded in 1996 and is based in Bethesda, Maryland. The company has conducted clinical and manufacturing activities in the United States and the United Kingdom, including operations associated with a cell-therapy manufacturing facility in Sawston, England. Linda Powers serves as chief executive officer, and Dr. Marnix L. Bosch has been a senior scientific leader involved in the company’s dendritic-cell technology and product development.

Key Stats

• Today's Range: $0.15 to $0.17
• 50-Day Range: $0.15 to $0.19
• 52-Week Range: $0.14 to $0.34
• Volume: 19.06 million shs
• Average Volume: 2.89 million shs
• Market Capitalization: $279.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Northwest Biotherapeutics Stock Analysis - MarketRank™

Northwest Biotherapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Northwest Biotherapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Northwest Biotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.44% of the float of Northwest Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Northwest Biotherapeutics has a short interest ratio ("days to cover") of 12.26, which indicates bearish sentiment.

Change versus previous month

Short interest in Northwest Biotherapeutics has recently increased by 1.73%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Northwest Biotherapeutics does not currently pay a dividend.

Dividend Growth

Northwest Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.53

News Sentiment

Northwest Biotherapeutics has a news sentiment score of -0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Northwest Biotherapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.40% of the stock of Northwest Biotherapeutics is held by insiders.

Percentage Held by Institutions

0.04% of the stock of Northwest Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NWBO
• Previous Symbol: NASDAQ:NWBO
• CIK: 1072379
• Web: www.nwbio.com
• Phone: (240) 497-9024
• Fax: 240-627-4121
• Employees: 20
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($18.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.16 million
• Net Margins: -1,736.35%
• Pretax Margin: -1,761.07%
• Return on Equity: N/A
• Return on Assets: -56.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: $1.38 million
• Price / Sales: 202.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -3.93

Miscellaneous

• Outstanding Shares: 1,782,960,000
• Free Float: 1,740,173,000
• Market Cap: $279.92 million
• Optionable: Not Optionable
• Beta: -0.62